EP 3532088 A1 20190904 - USE OF A SIRNA FOR TREATING CANCER
Title (en)
USE OF A SIRNA FOR TREATING CANCER
Title (de)
VERWENDUNG VON SIRNA ZUR BEHANDLUNG VON KREBS
Title (fr)
UTILISATION D'UN SIRNA POUR LE TRAITEMENT DES CANCERS
Publication
Application
Priority
- FR 1660439 A 20161027
- FR 2017052214 W 20170808
Abstract (en)
[origin: WO2018078225A1] The present invention concerns a composition comprising at least one siRNA, said siRNA hybridising with a coding or non-coding mRNA, in which it induces degradation or inhibits translation, the expression of said mRNA or of the protein for which it codes being implicated in a pathology, for the use of same in the prevention and/or the treatment of said pathology, said composition being formulated for a continuous systemic administration mode, and a device comprising such an administration mode.
IPC 8 full level
A61K 9/00 (2006.01); A61K 31/713 (2006.01); A61K 38/18 (2006.01); A61K 38/39 (2006.01); A61M 15/00 (2006.01)
CPC (source: EP US)
A61K 31/713 (2013.01 - EP US); A61K 38/1866 (2013.01 - EP US); A61K 38/1891 (2013.01 - EP US); A61K 38/39 (2013.01 - EP US); A61M 5/142 (2013.01 - EP US); A61P 35/00 (2017.12 - EP US); A61P 35/02 (2017.12 - EP); A61P 35/04 (2017.12 - EP); C12N 15/1138 (2013.01 - EP US); C12Q 1/6851 (2013.01 - US); C12Q 1/686 (2013.01 - US); C12N 2310/14 (2013.01 - EP)
Citation (search report)
See references of WO 2018078225A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2018078225 A1 20180503; CA 3041624 A1 20180503; CN 110352069 A 20191018; EP 3532088 A1 20190904; FR 3058061 A1 20180504; JP 2019535816 A 20191212; US 2019336520 A1 20191107
DOCDB simple family (application)
FR 2017052214 W 20170808; CA 3041624 A 20170808; CN 201780081248 A 20170808; EP 17771797 A 20170808; FR 1660439 A 20161027; JP 2019546084 A 20170808; US 201716345586 A 20170808